Table 3:

Treatment Adverse Events (no. of events)

	Bevacizumab alone (n=72)					Bevacizumab + Everolimus (n=73)
	Grade 1	Grade 2	Grade 3	Grade 4	Grade 5	Grade 1	Grade 2	Grade 3	Grade 4	Grade 5
Blood/Lymphatics
Neutropenia1	5	1	0	0	0	11	15	5	0	0
Anemia1	18	5	0	0	0	24	22	1	0	0
Thrombocytopenia1	6	2	0	0	0	28	10	1	0	0
Cardiac	1	0	1	0	0	5	1	0	1	0
Ear/labyrinth	2	0	0	0	0	2	20	0	0	0
Gastrointestinal
Nausea1	19	3	4	0	0	13	12	6	0	0
Vomiting	5	4	2	0	0	13	7	5	0	0
Other GI1,2	34	8	1	0	0	23	22	13	1	0
General/	43	9	1	0	0	34	20	7	0	0
administrative site1
Hepatobiliary	0	0	0	0	0	0	2	0	0	0
Immune system	0	0	0	0	0	0	2	0	0	0
Infections	1	6	2	0	0	2	7	6	1	0
Metabolism/nutrition1,2	18	4	4	1	0	15	14	13	1	0
Musculoskeletal/ connective tissue	24	6	1	0	0	12	8	4	0	0
Nervous system	21	6	2	0	0	28	9	3	0	0
Peripheral neuropathy	10	1	0	0	0	12	1	1	0	0
Other investigations	18	4	2	0	0	18	20	2	0	0
Psychiatric	5	1	0	0	0	8	4	0	0	0
Renal/urinary	7	0	2	0	0	8	5	1	0	0
Respiratory/thoracic1	26	3	0	0	0	26	12	4	1	0
Skin/subcutaneous1	16	2	0	0	0	24	10	2	0	0
Vascular disorders	7	11	10	2	1	4	7	12	1	1

^1–Toxicities are significantly associated with treatment at the 5% level when classified as mild (Grade <=1), moderate (grade =2) and severe (Grade >=3) (highlighted as a light shadow in table)

^2–Toxicities are significantly associated with treatment at the 5% level when classified as mild to moderate and severe (grade 3–5 non-hematologic and grade 4–5 hematologic events) (highlighted as a dark shadow in table)